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Abstract 
 
 In Ayurveda, Lodhra is a used for many ailments either as single ingredient or part of formulation. It has been 
used for thousands of years to manage Kapha-Pitta based disease and specially to improve women's health in 
Ayurvedic science. Observations: Among these ailment, it was also indicated for Prameha (Diabetes) in many 
authoritative books of Ayurveda (First schedule of The Drugs and Cosmetics Act 1940). Contemporary science also 
proofs its antidiabetic property by recent researches. The clinical course and prognosis of health and life of diabetic 
patient are now largely determined by so called complications of diabetes. Other properties of Lodhra viz. healing 
property, antioxidant property, anti-microbial property, anti-ulcer property etc. may be utilized against diabetic 
complications. Aim and Objective: Author present here comprehensive review of Lodhra for its antidiabetic property 
and investigate its pharmacodynamics that may help to keep away diabetic complications and other problems of daily 
life. 
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Introduction 
Indian Subcontinent was served by Ayurveda 
since 1000 B.C. with objectives to achieve physical, 
mental, social and spiritual health by its treatment and 
life style wisdom (1). In 21st century, when world 
mindset is being attracted towards nature based medical 
service and start looking towards traditional system of 
medication, scholars are trending towards plant based 
researches. Contemporary science flourish data as a 
large evidence that has been available to show the huge 
potential of medicinal plants used in various traditional 
systems and to put a current scientific proof for ancient 
wisdom (2).  In sanskrit “Lodhra” is meant for 
‘Propitious’& ‘Tilaka’, as the bark of the tree was used 
in making the Tilaka mark on the forehead so the plant 
was named as Lodhra (3). In Europe, it was formerly 
known as a Cinchona bark and had been known at 
various time as “Encorce de lautour”, “China nova” & 
“China paraquatan”(4). In Many of the traditional 
systems, one common vernacular name has been used 
for plants of different species leading to adulteration or 
accidental misuse of the plant (5). Symplocos racemosa 
Roxb., which is 6 to 8.5 metres tall, found abundantly in 
the plains and lower hills throughout India. Lodhra bark 
has astringent, styptic, anti-inflammatory, and 
antimicrobial Properties. No adverse effect of Lodhra 
powder is reported when taken in recommended doses. 
It is also found safe for the baby if a nursing mother is 
taking this medication. However, Lodhra powder should 
not be used for along duration during pregnancy (6). 
Diabetes is fast spreading metabolic vascular 
syndrome of multiple aetiologies characterise by 
chronic hypoglycaemia with distribution of 
carbohydrates, fats, protein metabolism (7). In current 
era, the complications related with diabetes are more 
dangerous than diabetes itself, so treatment approach 
are modifying to treat diabetes along with prevention of 
its complications. WHO (World Health Organization) 
have reported many complications that may be kept 
away by using the preventive pharmacology of Lodhra 
viz. antioxidant property, anti-microbial property, anti-
ulcer property etc.  
 
Phytoconstituents of Lodhra 
 Mostly the bark of the Lodhra (Symplocos 
racemosa) was used in Ayurvedic formulation that 
contains Colloturine, Harman (Loturine) and Loturidine 
and Proanthocyanidin-3-monoglucofuranosides of 7-O-
methyl-and 4’-Omethyl- leucopelargonidin. Betulinic, 
oleanolic, acetyl oleanolic and ellagic acids are also 
reported from the plant. Glycosides, isolated from the 
ethanolic extract of the stembark, are highly astringent 
and are reported to be responsible for the medicinal 
properties of the bark (8). Other chemical constituents 
are also reported in different researches (Table-1). 
 
Properties and Indications of Lodhra in Ayurveda 
 Lodhra is having Laghu, Ruksha guna, Kashaya 
rasa, Katu veerya and Sheeta vipaka according to 
Ayurvedic science. It is Kapha-Pitta shamak due to its 
Kashaya and Sheeta property that was utilized in 
treatment of Kaphaj prameha. It has been used as netra 
hitkara & rakta dosha nashaka (17). Due to its pitta 
and kapha dosha pacifying activities i.e., it mitigates 
vitiated forces (doshas) of body. It is also helpful in 
cleaning of wound, holds bleeding & initiates fast 
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healing process. It was used as single ingredient as well 
as part of the formulation. In case of Prameha, Lodhra 
was used in Pramehaghna yoga (Antidiabetic 
formulations) and its other properties may be utilized 
against complications arises either due to diabetes 
mellitus of during the disease (Table-2).    
 
Table.1. Phytoconstituents of Symplocos species 
Table.2.    Lodhra in  Pramehaghna yoga 
(Antidiabetic formulations) 
 
 
(G.N.- Gada Nigraha,  AH- Astang Hrdya, BR- 
Bhaisajya Ratnawali, Sh. S.- Sharangdhar Samhita, Ch. 
Chi- Charak Chikitsa sthan) 
 
Lodhra for Diabetes 
 Diabetes is a chronic, metabolic disease 
characterized by elevated levels of blood glucose (or 
blood sugar), which leads over time to serious damage 
to the heart, blood vessels, eyes, kidneys, and nerves 
(18). Hexane extract of S. cochinchinensis leaves has 
potential of antidiabetic property to treat type 2 
diabetes. The methanolic extract of stem bark shows 
significant decrease in plasma insulin and liver 
glycogen levels in treated diabetic rats. The glycemic 
response recorded in Symplocos cochinchinensis 
hexane extract treated group indicated that the extract 
had the potential to improve insulin sensitivity. The 
Symplocos species aggravates the degree of impairment 
slightly but significantly, indicating the potential 
function in reducing insulin resistance (19). The 
ethanolic extract of leaves showed hypoglycemic 
activity in rats and anticancer activity against Friend 
virus- leukaemia (solid) in mice. The extract of the 
leaves and of stems showed activity against human 
epidermoid carcinoma of the nasopharynx in tissue-
culture (8). Symplocos cochinchinensis groups showed 
S. 
N
o. 
Formulation 
containing 
Lodhra as an 
ingredient 
Indications 
(Rogadhikar) 
References 
1 Rodhrasava 
(lodhrasava) 
Kaphaj 
Prameha 
G.N.Prameh
a/42-45; 
A.H.Chi.12/
25-28 . 
2 Vidangaristha Prameha G.N.Asava.3
7-41; 
B.R.37/19 ; 
Sh.S.M.Kh.1
0/47-52 . 
3 Lodhradi 
Kashaya 
Kaphaj 
Prameha 
Vaidya 
Chimtamani, 
Prameha 
prakaranam 
4 Lodhradi 
Kashaya 
Madhumeha Basavrajiya
m 9/59 
5 Haritkyadi 
Kashaya 
Kaphaj 
Prameha 
Ch.  Chi. 
6/27 ; B. R. 
37/20-22 
6 Madhvasava 
(Lodhrasava) 
KaphaPittaj 
Prameha 
Ch.  Chi. 
6/41-44 
7 Usiradi kasaya Pittaj 
Prameha 
B. R. 37/24 
Sr. 
No. 
Class Constituents References 
1 Flavanol 
glucosides 
Symplocoside, 
Symposide, 
Leucopelargonid
in 3-Glucoside, 
Ellagic Acid, 
Rhamnetin 3-
Galactoside. 
Triterpenoids: 
19 Α-
Hydroxyarjunoli
c Acid-3, 28-O-
Bis-Β-
Glucopyranosid
es, 19 Α-
Hydroxyasiatic 
Acid-3, Betulin, 
Oleanolic Acid, 
Β- Sitosterol & 
Α-Amyrin 
9,10 
2 Alkaloids Loturine, 
Isoloturine & 
Harmane 
11 
3 Phenolic 
Glycosides 
Benzoylsalirepo
side ,Symconosi
de A & 
Symconoside 
B , 
Symplocuronic 
Acid & 
Sympocernoside
, b-amyrin, b-
sitosterol 
12,13,14 
4 Ethyl 
Substituted 
Glycosides 
Ketochaulmoogr
ic Acid, 
Nonaeicosanol, 
Triacontyl 
Palmitate, 
Methyl 
Triacontanoate 
and one new 1-
Ethylbrachiose-
3´-Acetate 
15 
5 Triterpenoid betulin and 
oleanolic acid 
16 
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significant hypoglycemic activity along with improved 
insulin sensitivity possibly by improving one or more 
defects viz. insulin receptor, insulin receptor substrate, 
glucose transporters or enzymes involved in 
phosphorylation of glucose (20,21). Secretion and/or 
insulin action or could be related to the interference on 
absorption of dietary carbohydrates as well as 
disaccharides in small intestine leading to the 
suppression of meal induced increase of plasma glucose 
thus showing hypoglycemic activity (22). 
 
Management of Diabetic Complication 
 Diabetes complications are divided into 
microvascular (due to damage to small blood vessels) 
and macrovascular (due to damage to larger blood 
vessels). Microvascular complications include damage 
to eyes (retinopathy) leading to blindness, to kidneys 
(nephropathy) leading to renal failure and to nerves 
(neuropathy) leading to impotence and diabetic foot 
disorders (which include severe infections leading to 
amputation). Macrovascular complications include 
cardiovascular diseases such as heart attacks, strokes 
and insufficiency in blood flow to legs. There is 
evidence from large randomized-controlled trials that 
good metabolic control in both type 1 and 2 diabetes 
can delay the onset and progression of these 
complications. Good metabolic control can delay the 
onset and progression of diabetic retinopathy.  control 
of high blood glucose, control of high blood pressure, 
intervention with medication in the early stage of 
kidney damage, and restriction of dietary protein. (23) 
The clinical course and prognosis of health and life of 
diabetic patient are now determined by so called 
complications of diabetes. The characteristic 
progressive damage to the eyes, kidney, and nerves and 
heightened susceptibility to heart disease, gangrene and 
stroke are most prominent in metabolic disorders. These 
complications are Diabetic microangiopathy 
(Progressive change in capillaries leads too renal and 
retinal disease), Arterial disease, local tissue damage 
(reason behind Neuropathy and cataract), Diabetic 
neuropathy (Malfunctioning of cardiovascular system, 
respiratory system, urinary and sexual function) and 
infection (Tuberculosis, Fungal infection to skin & UTI 
or anaerobic infection of deep tissues). These 
complications can be managed by improvement of 
metabolic control, prevention of vascular disease, 
prevention of infections and preservation of organ 
function) (24). 
 Significant decrease in plasma and liver TC (total 
Cholesterol), TG (triglyceride) and lipids recorded in 
Lodhra groups indicates the role of Symplocos in 
preventing dyslipidemia and lipotoxicity. Synthetic 
antidiabetic drugs commercially available in the market 
are often not able to tackle dyslipidemia, thus raising 
the risk of cardiovascular complications. Hence, these 
results can be considered significant against diabetic 
dyslipidemia. These results are also in accordance with 
previously reported lipid lowering property in high fat 
diet–low STZ induced hyperglycemic rats (25).  
 
Antibacterial Activity- Antibacter ial proper ty helps 
the diabetic patient to fight against infections caused 
over skin, urinary tract etc. Its antibacterial property is 
helpful in prevention of complications. Ethanolic 
extract of S. racemosa Roxb shows good antibacterial 
activity as compared to petroleum ether, but it has poor 
antibacterial activity against gram negative 
microorganism like P. aeruginosa and E. Coli (26). 
Methanolic extracts of leaves, root and stem barks of S. 
cochinchinensis and their fractions obtained by 
partition (petrol, dichloromethane and ethyl acetate) 
were screened for antimicrobial activity. All crude 
extracts and fractions showed a broad spectrum of 
antibacterial activity that was enhanced on fractionation 
(27).).  
 
Anthelmintic effect: Anthelminthic proper ty of the 
Lodhra was helpful to prevent metabolic disorder 
caused due to helminths. The anthelmintic activity of 
petroleum ether, chloroform and ethanol extract of bark 
S. racemosa on adult Indian earthworms. This reveals 
that the Ethanolic extract had more anthelmintic 
property as compared to other extract (28).  
 
Anti-inflammatory activity: Major  complications in 
diabetes mellitus are the reason behind inflammation in 
body tissues, organs etc. so the anti-inflammatory 
property may be utilized against complications. It may 
be used as preventive measure against diabetic 
complications and for the patients relieves. Methanol 
extract of leaves have effective in-vitro anti-
inflammatory activity. The extract also showed 
significant in-vivo anti-inflammatory activity (53%) at 
the dose of 400mg/ml (29).  
 
Anti-oxidant activity: Antioxidant proper ty are 
helping in person to avoid many ailments and keep 
body tissues healthy. It scavenges the harmful free 
radicles that are either accumulated in the body or 
produces during abnormalities in metabolism. Thus it 
help in protection of vital cell against metabolic 
disorder and complications of diabetes. The methanol 
extract of Lodhra leaves showed very good scavenging 
activity on 2,2-diphenyl- picrylhydrazyl (DPPH), 
hydroxyl, nitric oxide radicals, as well as high reducing 
power. The extract also showed strong suppressive 
effect on lipid per-oxidation (30).  
 
Anti-ulcer property: Antiulcer  proper ty of Lodhra 
may be utilized against tissue damage in gastro-
intestinal tract and it may play a preventive role when 
used in antidiabetic formulations. The aqueous and 
ethanolic extracts of S. racemosa showed anti-ulcer 
property. Anti-secretory activity (decrease in gastric 
volume) and reduction in free and total acidity of the 
extracts at 500mg/kg was noticed in pylorus ligation 
induced ulcer model (31).  
 
Hypolipidemic activity: Hypolipidemic activities of 
ethanolic extracts of S. racemosa (ESSR) were studied 
by triton-WR1339 (acute) and high fat diet induced 
(chronic) hyperlipidemic rat models. ESSR treatment 
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prevented the increased formation of malondialdehyde 
(MDA) in liver and restored the depleted liver 
antioxidants, glutathione, superoxide dismutase, 
catalase significantly. It also restores TC, TG, VLDL, 
HDL and LDL level. The hypolipidemic activity of 
ESSR may be due to presence of flavonoids phenolic 
compounds, phenolic glycosides and steroids (32). 
Methanolic extract of bark showed antilipidemic 
activity as evidenced by significant decrease in serum 
TC, TG, LDL-C levels and significant increase in HDL-
C level in treated diabetic rats. It also restored the 
altered plasma enzymes (SGOT, SGPT and ALP), total 
protein, urea and creatinine levels to near normal (33).  
 
Neuro-supportive role:  Lodhra extract are having 
nervine tonic and good healing properties that may be 
utilized in diabetic wound healing as well as nervine 
damage. It may play a preventive role over neuropathy 
complications as well as body tissue damage 
complications. Locoracemosides A, B and C from n-
butanol soluble extract from bark of S. racemosa 
showing in vitro inhibitory activity against α-
chymotrypsin (34). 
 
Hepato-protective activity: High blood sugar  are 
reported for damaging the liver tissue and altering the 
metabolic equilibrium. Liver is key player for 
metabolism in the body so protection of hepatic tissue 
may impart to fight against diabetic complications. 
Ethanolic extract of bark of S. racemosa showed 
significant dose-dependent restoration of serum 
enzymes, bilirubin, albumin, total proteins and 
antioxidant levels against carbon tetrachloride induced 
hepatic damage in rats. Notable improvements were 
observed morphologically and histopathologically (35).  
 
Lipoxygenase and urease inhibitory activity: These 
enzymes promote the development of kidney stones, 
polynephritis, peptic ulcer disease etc. so inhibition of 
this enzyme helps in proper metabolism and prevent 
from additional problems due to complications. 
Phytoconstituent, 1-ethyl brachiose-3´-acetate and 
triacontyl palmitate displayed the inhibitory potential 
against lipoxygenase and urease enzyme (36). 
Triacontanyl palmitate isolated from n-hexane soluble 
fraction of bark of S. racemosa inhibit the urease 
enzymes in a concentration-dependent manner (37).  
 
Conclusion 
 Diabetes is grasping the human population in 
accelerated manner due to disturbance in lifestyle, mind 
status and genome. The complications arise due to 
diabetes or during diabetic condition was more 
concerning prospective in treatment approach now days. 
Lodhra was used in antidiabetic formulations in 
Ayurveda for the management of Prameha (Diabetes).  
In 21st century when the research involves the language 
of modern science, provide data based evidence about 
antidiabetic property of Lodhra. Other 
pharmacodynamics of Lodhra can be utilized against 
diabetic complications and it play major role in overall 
management of diabetic patients when used in 
formulation. Alongside it also proof that ancient 
wisdom was already utilizing these properties for the 
management of Prameha. 
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